COMMUNIQUÉS West-GlobeNewswire

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
16/03/2026
NDA based on positive clinical results from the SUMMIT pivotal trial in which bezuclastinib demonstrated clear clinical benefit across all symptom domains WALTHAM, Mass. and BOULDER, Colo., March 16, 2026 (GLOBE [...]
Extendicare Announces March 2026 Dividend of C$0.0441 per Share
16/03/2026
MARKHAM, Ontario, March 16, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month [...]
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
16/03/2026
• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026 • DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options • Award reflects Daré's [...]
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
16/03/2026
MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
Recludix Pharma Promotes Executive Leaders Following Recent Corporate Accomplishments
16/03/2026
– Ajay Nirula, M.D., Ph.D., will now also serve as president, in addition to his role as head of research and development - Catherine Bovenizer, C.P.A., has been named chief financial officer, following her tenure as [...]
Heartflow Builds Evidence Base Across the Heart Disease Care Continuum, From Precision Risk Stratification to CT-Guided Intervention Planning
16/03/2026
Three presentations at ACC reinforce Heartflow’s AI-powered technology predicts MACE, drives superior lipid outcomes and results in cost-effective care First patient enrolled in p ioneering N AVIGATE - PCI Registry [...]
Nadia Care Raises $12 Million to Expand Community-Centered Maternal Care Model Across the U.S.
16/03/2026
Expansion in DC, Maryland, and Tennessee Markets on the Heels of Excellent Outcomes WASHINGTON, March 16, 2026 (GLOBE NEWSWIRE) -- Nadia Care, the maternal health company formerly known as Cayaba Care, announced a $12 [...]
Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value
16/03/2026
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced the successful [...]
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
16/03/2026
Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro , in vivo and non-human primate study results, that support development candidates in Acumen’s [...]
Cronos Group Inc. to Speak at the 38th Annual ROTH Conference
16/03/2026
TORONTO, March 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
16/03/2026
NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research. Minutes are [...]
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
16/03/2026
FDA confirmed givastomig’s potential eligibility for an accelerated approval pathway NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective response rate (ORR) as [...]
Minutes from Extraordinary General Meeting
16/03/2026
An extraordinary general meeting of PCI Biotech Holding ASA (“the Company”) took place today, 16 March 2026. All the matters on the agenda were approved in accordance with the proposals set out in the meeting notice, [...]
Doctomatic Appoints Tech Veteran Bill Josko as Head of Americas to Scale AI-Driven Remote Patient Monitoring
16/03/2026
BARCELONA, Spain, March 16, 2026 (GLOBE NEWSWIRE) -- Doctomatic, an AI-native platform for remote patient management, announces the appointment of Bill Josko as Head of Americas. Josko, a seasoned executive with more [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
16/03/2026
COPENHAGEN, Denmark, March 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
Weight Watchers Announces Fourth Quarter and Full Year 2025 Results
16/03/2026
2025 Total Revenue and Adjusted EBITDA 1,2 above high end of previously provided guidance Total End of Period Subscribers of 2.8 million; End of Period Clinical Subscribers of 130 thousand, up 42% year-over-year with [...]
Tilray Brands Enters Agreement to Acquire BrewDog’s Key U.S. Assets, Expanding Its U.S. Craft Beer Platform
16/03/2026
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the [...]
Novo Nordisk A/S - share repurchase programme
16/03/2026
Bagsværd, Denmark, 16 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
16/03/2026
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea [...]

Pages